Triplet chemotherapy for advanced lung cancer
Author Information
Author(s): Niho S, Kubota K, Goto K, Ohmatsu H, Matsumoto T, Kakinuma R, Nishiwaki Yutaka
Primary Institution: National Cancer Center Hospital East, Chiba, Japan
Hypothesis
The study aimed to assess the efficacy and toxicity of triplet chemotherapy consisting of vinorelbine, gemcitabine, and cisplatin in patients with advanced non-small cell lung cancer.
Conclusion
Triplet chemotherapy containing vinorelbine, gemcitabine, and cisplatin is effective in treating chemotherapy-naïve patients with advanced non-small cell lung cancer, but it causes unacceptable rates of febrile neutropenia.
Supporting Evidence
- The objective response rate was 48%, with 16 partial responses among 33 patients.
- The median survival time was 13.5 months, with a one-year survival rate of 61%.
- Grade 4 neutropenia occurred in 72% of patients, indicating significant toxicity.
Takeaway
This study tested a combination of three cancer drugs to see if they help people with advanced lung cancer. It worked for some, but it also made many people very sick.
Methodology
Patients received intravenous infusions of vinorelbine, gemcitabine, and cisplatin on days 1 and 8 at 3-week intervals, and their responses and toxicities were evaluated.
Potential Biases
The study was conducted at a single institution, which may introduce selection bias.
Limitations
The study had a small sample size and high rates of severe toxicity, which may limit the generalizability of the results.
Participant Demographics
The majority of participants were male (79%) with a median age of 63 years; most had stage IV disease or recurrence after surgical resection.
Statistical Information
P-Value
0.035
Confidence Interval
95% CI: 31–66%
Statistical Significance
p<0.05
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website